The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol
The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an o...
Saved in:
| Published in | Engineering (Beijing, China) Vol. 6; no. 10; pp. 1199 - 1204 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Ltd
01.10.2020
THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2095-8099 2096-0026 |
| DOI | 10.1016/j.eng.2020.06.011 |
Cover
| Abstract | The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an ongoing multicenter and blind randomized controlled trial (RCT), is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. A total of 240 participants with COVID-19 are scheduled to be enrolled in this trial. Participants with positive tests of throat swab virus nucleic acid are randomized (1:1) into two groups: standard therapy plus TZV or standard therapy plus placebo for a 7-day treatment with a 21-day follow-up. The primary outcome is the time to clinical improvement of the subjects. Secondary outcomes include clinical improvement rate, time to alleviation of fever, mean time and proportion of obvious inflammatory absorption in the lung, conversion rate of repeated negative virus nucleic acid tests, mortality rate, and conversion rate to severe and critically severe patients. Adverse events, serious adverse events, liver function, kidney function, and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19. |
|---|---|
| AbstractList | The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an ongoing multicenter and blind randomized controlled trial (RCT), is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. A total of 240 participants with COVID-19 are scheduled to be enrolled in this trial. Participants with positive tests of throat swab virus nucleic acid are randomized (1:1) into two groups: standard therapy plus TZV or standard therapy plus placebo for a 7-day treatment with a 21-day follow-up. The primary outcome is the time to clinical improvement of the subjects. Secondary outcomes include clinical improvement rate, time to alleviation of fever, mean time and proportion of obvious inflammatory absorption in the lung, conversion rate of repeated negative virus nucleic acid tests, mortality rate, and conversion rate to severe and critically severe patients. Adverse events, serious adverse events, liver function, kidney function, and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19. The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an ongoing multicenter and blind randomized controlled trial (RCT), is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. A total of 240 participants with COVID-19 are scheduled to be enrolled in this trial. Participants with positive tests of throat swab virus nucleic acid are randomized (1:1) into two groups: standard therapy plus TZV or standard therapy plus placebo for a 7-day treatment with a 21-day follow-up. The primary outcome is the time to clinical improvement of the subjects. Secondary outcomes include clinical improvement rate, time to alleviation of fever, mean time and proportion of obvious inflammatory absorption in the lung, conversion rate of repeated negative virus nucleic acid tests, mortality rate, and conversion rate to severe and critically severe patients. Adverse events, serious adverse events, liver function, kidney function, and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19.The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an ongoing multicenter and blind randomized controlled trial (RCT), is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. A total of 240 participants with COVID-19 are scheduled to be enrolled in this trial. Participants with positive tests of throat swab virus nucleic acid are randomized (1:1) into two groups: standard therapy plus TZV or standard therapy plus placebo for a 7-day treatment with a 21-day follow-up. The primary outcome is the time to clinical improvement of the subjects. Secondary outcomes include clinical improvement rate, time to alleviation of fever, mean time and proportion of obvious inflammatory absorption in the lung, conversion rate of repeated negative virus nucleic acid tests, mortality rate, and conversion rate to severe and critically severe patients. Adverse events, serious adverse events, liver function, kidney function, and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19. |
| Author | Wang, Yongchen Li, Kang Wang, Yu Yu, Kaijiang Ma, Hongli Zhu, Liying Zhao, Mingyan Hou, Yan Zhang, Min Cai, Benzhi Qin, Huichao Hu, Xiaoli Yang, Baofeng Li, Yue Gao, Jingshu Wu, Xiaoke Xu, Wanhai Du, Zhimin Zhang, Yong |
| Author_xml | – sequence: 1 givenname: Xiaoke surname: Wu fullname: Wu, Xiaoke organization: Department of Pharmacology & State–Province Key Laboratories of Biomedicine-Pharmaceutics of China & Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacology, Harbin Medical University, Harbin 150001, China – sequence: 2 givenname: Kaijiang surname: Yu fullname: Yu, Kaijiang organization: The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 3 givenname: Yongchen surname: Wang fullname: Wang, Yongchen organization: The Second Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 4 givenname: Wanhai surname: Xu fullname: Xu, Wanhai organization: The Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 5 givenname: Hongli surname: Ma fullname: Ma, Hongli organization: First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China – sequence: 6 givenname: Yan surname: Hou fullname: Hou, Yan organization: Department of Pharmacology & State–Province Key Laboratories of Biomedicine-Pharmaceutics of China & Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacology, Harbin Medical University, Harbin 150001, China – sequence: 7 givenname: Yue surname: Li fullname: Li, Yue organization: The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 8 givenname: Benzhi surname: Cai fullname: Cai, Benzhi organization: The Second Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 9 givenname: Liying surname: Zhu fullname: Zhu, Liying organization: The Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 10 givenname: Min surname: Zhang fullname: Zhang, Min organization: Heilongjiang Provincial Hospital, Harbin Institute of Technology, Harbin 150030, China – sequence: 11 givenname: Xiaoli surname: Hu fullname: Hu, Xiaoli organization: Heilongjiang Provincial Hospital, Harbin Institute of Technology, Harbin 150030, China – sequence: 12 givenname: Jingshu surname: Gao fullname: Gao, Jingshu organization: First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China – sequence: 13 givenname: Yu surname: Wang fullname: Wang, Yu organization: First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China – sequence: 14 givenname: Huichao surname: Qin fullname: Qin, Huichao organization: First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China – sequence: 15 givenname: Mingyan surname: Zhao fullname: Zhao, Mingyan organization: The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 16 givenname: Yong surname: Zhang fullname: Zhang, Yong organization: Department of Pharmacology & State–Province Key Laboratories of Biomedicine-Pharmaceutics of China & Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacology, Harbin Medical University, Harbin 150001, China – sequence: 17 givenname: Kang surname: Li fullname: Li, Kang organization: Department of Pharmacology & State–Province Key Laboratories of Biomedicine-Pharmaceutics of China & Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacology, Harbin Medical University, Harbin 150001, China – sequence: 18 givenname: Zhimin surname: Du fullname: Du, Zhimin organization: The Second Affiliated Hospital, Harbin Medical University, Harbin 150001, China – sequence: 19 givenname: Baofeng surname: Yang fullname: Yang, Baofeng email: yangbf@ems.hrbmu.edu.cn organization: Department of Pharmacology & State–Province Key Laboratories of Biomedicine-Pharmaceutics of China & Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacology, Harbin Medical University, Harbin 150001, China |
| BookMark | eNp9kU1r20AQhpeS0nw0P6A3HXuRMvuhXamFQnDd1hBIoW6vy2g166yRtelKNri_vrIdCukhpx123veZYd5LdtbHnhh7x6HgwPXNuqB-VQgQUIAugPNX7EJArXMAoc-OdZlXUNfn7HoY1gDASw4GqjfsXIpKGlPCBZsvHyibex8cun2GfZv9QE_jPos-W6aAf3AXUugzH1M2u_-1-Jzz-kN2e-x12fcUx-hi95a99tgNdP30XrGfX-bL2bf87v7rYnZ7lztVqzFXjTCGG18iNhUqVNI0lW65awWaVjve8GnpSnFpvC61BNV4KtsGyBsUoOUVW5y4bcS1fUxhg2lvIwZ7_IhpZTGNwXVkQUJLvlFCl6WSdYOl84SkhDOtqvDA-nRiPW6bDbWO-jFh9wz6vNOHB7uKO2ukFEqqCfD-CZDi7y0No92EwVHXYU9xO9hJZDivZQWTlJ-kLsVhSOT_jeFgD2natZ3StIc0LWg7pTl5zH8eF0YcQzxsE7oXnR9PTpqi2AVKdnCBekdtSOTG6VbhBfdflBu4JA |
| CitedBy_id | crossref_primary_10_3389_fmicb_2020_587944 crossref_primary_10_5817_CSF2021_1_18 crossref_primary_10_1016_j_micpath_2022_105615 crossref_primary_10_1080_14787210_2022_1997587 crossref_primary_10_26442_00403660_2024_05_202770 crossref_primary_10_5817_CSF2022_6_239 crossref_primary_10_1007_s10870_022_00973_x crossref_primary_10_37489_0235_2990_2021_66_7_8_13_19 crossref_primary_10_1016_j_bioorg_2021_105016 crossref_primary_10_3390_ijms232314537 crossref_primary_10_1007_s10593_021_02927_1 crossref_primary_10_1016_j_xphs_2020_11_016 crossref_primary_10_3390_biomed3020025 crossref_primary_10_1016_j_eng_2020_08_011 |
| Cites_doi | 10.1038/s41422-020-0282-0 10.1056/NEJMoa2002032 10.1097/CM9.0000000000000819 10.1038/s41467-019-13940-6 10.1128/AAC.01186-09 10.1016/S0140-6736(20)30421-9 10.1001/jama.2020.1585 10.5582/bst.2020.01020 10.1074/jbc.AC120.013056 10.1016/S0140-6736(20)30183-5 10.1080/22221751.2020.1729071 |
| ContentType | Journal Article |
| Copyright | 2020 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. 2020 |
| Copyright_xml | – notice: 2020 – notice: 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. – notice: 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. 2020 |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1016/j.eng.2020.06.011 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 2096-0026 |
| EndPage | 1204 |
| ExternalDocumentID | oai_doaj_org_article_030defb42655439ba5cfeae42c7d48a6 PMC7332434 10_1016_j_eng_2020_06_011 S2095809920301697 |
| GroupedDBID | 0R~ 0SF 1-T 5VR 6I. 92H 92I 92R 93N AACTN AAEDW AAFTH AALRI AAXUO ABMAC ACGFS ACHIH ADBBV AEXQZ AFTJW AFUIB AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ BCNDV CCEZO CEKLB EBS EJD FDB GROUPED_DOAJ IPNFZ M41 NCXOZ O9- OK1 RIG ROL SSZ TCJ TGT -SC -S~ AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKRWK AKYEP CAJEC CITATION Q-- U1G U5M 7X8 5PM |
| ID | FETCH-LOGICAL-c494t-4b27717f5aab8a4a437b86d1cd2a7d6c1b109584137f656304bfe5db0ef7a2063 |
| IEDL.DBID | DOA |
| ISSN | 2095-8099 |
| IngestDate | Mon Sep 08 19:52:33 EDT 2025 Thu Aug 21 14:11:43 EDT 2025 Thu Jul 10 22:11:35 EDT 2025 Thu Apr 24 23:02:40 EDT 2025 Tue Jul 01 02:18:49 EDT 2025 Thu Jul 20 20:17:16 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Efficacy Pneumonia SARS-CoV-2 Safety Coronavirus disease 2019 Triazavirin |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-4b27717f5aab8a4a437b86d1cd2a7d6c1b109584137f656304bfe5db0ef7a2063 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
| OpenAccessLink | https://doaj.org/article/030defb42655439ba5cfeae42c7d48a6 |
| PMID | 32837750 |
| PQID | 2437119380 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_030defb42655439ba5cfeae42c7d48a6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7332434 proquest_miscellaneous_2437119380 crossref_primary_10_1016_j_eng_2020_06_011 crossref_citationtrail_10_1016_j_eng_2020_06_011 elsevier_sciencedirect_doi_10_1016_j_eng_2020_06_011 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-01 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Engineering (Beijing, China) |
| PublicationYear | 2020 |
| Publisher | Elsevier Ltd THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company – name: Elsevier |
| References | Kiselev, Deeva, Mel'nikova, Kozeletskaia, Kiselev, Rusinov (b0095) 2012; 57 Wang, Cao, Zhang, Yang, Liu, Xu (b0065) 2020; 30 Huang, Wang, Li, Ren, Zhao, Hu (b0060) 2020; 395 Chen, Yang, Yang, Wang, Bärnighausen (b0005) 2020; 395 nhc.gov.cn [Internet]. Beijing: National Health Commission of the People’s Republic of China; [cited 2020 Mar 12]. Available from: http://www.nhc.gov.cn/xcs/yqtb/202003/37c1536b6655473f8c2120ebdc475731.shtml. Chinese. Guan, Ni, Hu, Liang, Qu, He (b0055) 2020; 382 National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 5). Beijing: The State Council of the People’s Republic of China; 2020 Feb 4 [cited 2020 Mar 11]. Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf. Chinese. Coronavirus disease (COVID-19) pandemic [Internet]. Geneva: World Health Organization; c2020 [cited 2020 Mar 11]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Loginova, Borisevich, Rusinov, Ulomskii, Charushin, Chupakhin (b0085) 2014; 59 Sheahan, Sims, Leist, Schäfer, Won, Brown (b0115) 2020; 11 Lu (b0075) 2020; 14 Wang, Hu, Hu, Zhu, Liu, Zhang (b0050) 2020; 323 Karpenko, Deev, Kiselev, Charushin, Rusinov, Ulomsky (b0080) 2010; 54 National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J 2020;133:1087–95. Zhang, Du, Li, Zheng, Yang, Hu (b0010) 2020; 9 Gordon, Tchesnokov, Feng, Porter, Götte (b0110) 2020; 295 Loginova, Borisevich, Rusinov, Ulomsky, Charushin, Chupakhin (b0090) 2015; 60 Tikhonova, Kuz'mina, Andronova, Tyushevskaya, Elistratova, Kuz'min (b0100) 2018; 99 Sheahan (10.1016/j.eng.2020.06.011_b0115) 2020; 11 10.1016/j.eng.2020.06.011_b0070 Loginova (10.1016/j.eng.2020.06.011_b0090) 2015; 60 Karpenko (10.1016/j.eng.2020.06.011_b0080) 2010; 54 10.1016/j.eng.2020.06.011_b0020 Zhang (10.1016/j.eng.2020.06.011_b0010) 2020; 9 Loginova (10.1016/j.eng.2020.06.011_b0085) 2014; 59 Lu (10.1016/j.eng.2020.06.011_b0075) 2020; 14 10.1016/j.eng.2020.06.011_b0105 Gordon (10.1016/j.eng.2020.06.011_b0110) 2020; 295 Wang (10.1016/j.eng.2020.06.011_b0065) 2020; 30 10.1016/j.eng.2020.06.011_b0015 Tikhonova (10.1016/j.eng.2020.06.011_b0100) 2018; 99 Wang (10.1016/j.eng.2020.06.011_b0050) 2020; 323 Huang (10.1016/j.eng.2020.06.011_b0060) 2020; 395 Chen (10.1016/j.eng.2020.06.011_b0005) 2020; 395 Kiselev (10.1016/j.eng.2020.06.011_b0095) 2012; 57 Guan (10.1016/j.eng.2020.06.011_b0055) 2020; 382 |
| References_xml | – reference: Coronavirus disease (COVID-19) pandemic [Internet]. Geneva: World Health Organization; c2020 [cited 2020 Mar 11]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. – volume: 323 start-page: 1061 year: 2020 end-page: 1069 ident: b0050 article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China publication-title: JAMA – volume: 382 start-page: 1708 year: 2020 end-page: 1720 ident: b0055 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N Engl J Med – volume: 9 start-page: 386 year: 2020 end-page: 389 ident: b0010 article-title: Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes publication-title: Emerg Microbes Infect – reference: National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 5). Beijing: The State Council of the People’s Republic of China; 2020 Feb 4 [cited 2020 Mar 11]. Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf. Chinese. – volume: 30 start-page: 269 year: 2020 end-page: 271 ident: b0065 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) publication-title: Cell Res – volume: 14 start-page: 69 year: 2020 end-page: 71 ident: b0075 article-title: Drug treatment options for the 2019-new coronavirus (2019-nCoV) publication-title: Biosci Trends – volume: 11 start-page: 222 year: 2020 ident: b0115 article-title: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV publication-title: Nat Commun – volume: 59 start-page: 3 year: 2014 end-page: 5 ident: b0085 article-title: Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture publication-title: Antibiot Khimioter – volume: 295 start-page: 4773 year: 2020 end-page: 4779 ident: b0110 article-title: The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus publication-title: J Biol Chem – volume: 99 start-page: 215 year: 2018 end-page: 223 ident: b0100 article-title: Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections publication-title: Kazanskiĭ Meditsinskiĭ Zhurnal – volume: 54 start-page: 2017 year: 2010 end-page: 2022 ident: b0080 article-title: Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication publication-title: Antimicrob Agents Chemother – volume: 395 start-page: 764 year: 2020 end-page: 766 ident: b0005 article-title: COVID-19 control in China during mass population movements at New Year publication-title: Lancet – volume: 60 start-page: 8 year: 2015 end-page: 11 ident: b0090 article-title: Investigation of prophylactic efficacy of Triazavirin against experimental forest-spring encephalitis on albino mice publication-title: Antibiot Khimioter – reference: nhc.gov.cn [Internet]. Beijing: National Health Commission of the People’s Republic of China; [cited 2020 Mar 12]. Available from: http://www.nhc.gov.cn/xcs/yqtb/202003/37c1536b6655473f8c2120ebdc475731.shtml. Chinese. – volume: 57 start-page: 9 year: 2012 end-page: 12 ident: b0095 article-title: A new antiviral drug Triazavirin: results of phase II clinical trial publication-title: Vopr Virusol – volume: 395 start-page: 497 year: 2020 end-page: 506 ident: b0060 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet – reference: National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J 2020;133:1087–95. – volume: 57 start-page: 9 issue: 6 year: 2012 ident: 10.1016/j.eng.2020.06.011_b0095 article-title: A new antiviral drug Triazavirin: results of phase II clinical trial publication-title: Vopr Virusol – volume: 60 start-page: 8 issue: 5–6 year: 2015 ident: 10.1016/j.eng.2020.06.011_b0090 article-title: Investigation of prophylactic efficacy of Triazavirin against experimental forest-spring encephalitis on albino mice publication-title: Antibiot Khimioter – volume: 30 start-page: 269 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0065 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro publication-title: Cell Res doi: 10.1038/s41422-020-0282-0 – volume: 59 start-page: 3 issue: 1–2 year: 2014 ident: 10.1016/j.eng.2020.06.011_b0085 article-title: Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture publication-title: Antibiot Khimioter – volume: 382 start-page: 1708 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0055 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N Engl J Med doi: 10.1056/NEJMoa2002032 – ident: 10.1016/j.eng.2020.06.011_b0070 doi: 10.1097/CM9.0000000000000819 – volume: 11 start-page: 222 issue: 1 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0115 article-title: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV publication-title: Nat Commun doi: 10.1038/s41467-019-13940-6 – volume: 54 start-page: 2017 issue: 5 year: 2010 ident: 10.1016/j.eng.2020.06.011_b0080 article-title: Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01186-09 – volume: 99 start-page: 215 issue: 2 year: 2018 ident: 10.1016/j.eng.2020.06.011_b0100 article-title: Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections publication-title: Kazanskiĭ Meditsinskiĭ Zhurnal – volume: 395 start-page: 764 issue: 10226 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0005 article-title: COVID-19 control in China during mass population movements at New Year publication-title: Lancet doi: 10.1016/S0140-6736(20)30421-9 – volume: 323 start-page: 1061 issue: 11 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0050 article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China publication-title: JAMA doi: 10.1001/jama.2020.1585 – ident: 10.1016/j.eng.2020.06.011_b0020 – volume: 14 start-page: 69 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0075 article-title: Drug treatment options for the 2019-new coronavirus (2019-nCoV) publication-title: Biosci Trends doi: 10.5582/bst.2020.01020 – volume: 295 start-page: 4773 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0110 article-title: The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus publication-title: J Biol Chem doi: 10.1074/jbc.AC120.013056 – ident: 10.1016/j.eng.2020.06.011_b0015 – volume: 395 start-page: 497 issue: 10223 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0060 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – ident: 10.1016/j.eng.2020.06.011_b0105 – volume: 9 start-page: 386 issue: 1 year: 2020 ident: 10.1016/j.eng.2020.06.011_b0010 article-title: Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2020.1729071 |
| SSID | ssj0001510708 ssib026970494 |
| Score | 2.2449737 |
| Snippet | The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has... |
| SourceID | doaj pubmedcentral proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1199 |
| SubjectTerms | Coronavirus disease 2019 Efficacy Pneumonia Research Coronavirus Disease 2019—Protocol Safety SARS-CoV-2 Triazavirin |
| Title | The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol |
| URI | https://dx.doi.org/10.1016/j.eng.2020.06.011 https://www.proquest.com/docview/2437119380 https://pubmed.ncbi.nlm.nih.gov/PMC7332434 https://doaj.org/article/030defb42655439ba5cfeae42c7d48a6 |
| Volume | 6 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT94wDI4Qp-2ABtvEuwHKpJ2QqiVt2jTcgL0IkAaTBohb5HzBO6EWQUGCX4_TD9Re2GXXxm1T24kfK-5jQr6rUiifK0gMZCwRRqaJwr0ywdgQYqMTz3080f11Uhyei-PL_HLU6ivWhHX0wJ3ifqATOh8MBhIMfJkykNvgwYvUSidKaMm2mWKjZKr7PxjTmq4dHWII3IaVGo402-IuX11hbpiylruT80lQarn7J7FphD2nlZOjUHTwgaz0GJLudnNfJUu-WiPvR8yCH8kczU_nkR4C7BOFytE_EHzzROtAz9DnnuFxgZIUISvdP704-plwtUN327Eb-vuubmr0kE_k_GB-tn-Y9B0TEiuUaFDXqcT8LOQApgQBIpOmLBy3LgXpCssNR3WUaAwZisgMJkzwuTPMBwkpopXPZLmqK79OqEMoV6QqWJQUBUuVkE5BlnEonWRWzAgbVKZtTyceu1rc6KFu7C8uvCsdtaxj7RznM7L9esttx6XxlvBetMOrYKTBbi-gc-jeOfS_nGNGxGBF3SOKDingoxZvvfvbYHGNqy0eoUDl64d7HekbOWLeks2InLjCZKLTkWpx3fJ2ywzRaya-_I8v-0rexQl3ZYUbZLm5e_CbCI8as9WuhBci-gnQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Efficacy+and+Safety+of+Triazavirin+for+COVID-19%3A+A+Trial+Protocol&rft.jtitle=Engineering+%28Beijing%2C+China%29&rft.au=Wu%2C+Xiaoke&rft.au=Yu%2C+Kaijiang&rft.au=Wang%2C+Yongchen&rft.au=Xu%2C+Wanhai&rft.date=2020-10-01&rft.issn=2095-8099&rft.volume=6&rft.issue=10&rft.spage=1199&rft_id=info:doi/10.1016%2Fj.eng.2020.06.011&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2095-8099&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2095-8099&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2095-8099&client=summon |